- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.08. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | 140 | GlobeNewswire (Europe) | -- Executing IND-enabling activities for next-generation PI3Ka pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027... ► Artikel lesen | |
| 04.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 21.07. | OnKure Aktie: H.C. Wainwright senkt Kursziel nach Neubewertung auf 21 US-Dollar | - | Investing.com Deutsch | ||
| 21.07. | H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes | 3 | Investing.com | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.07. | OnKure Therapeutics, Inc.: OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 | 2 | GlobeNewswire (USA) | ||
| 05.06. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.05. | OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37 | 4 | Seeking Alpha | ||
| 30.03. | Leerink cuts OnKure stock price target on strategic shift | 2 | Investing.com | ||
| 30.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Oppenheimer reiterates OnKure stock rating on pipeline shift | 1 | Investing.com | ||
| 27.03. | OnKure Therapeutics prices $150M oversubscribed private placement | 1 | Seeking Alpha | ||
| 27.03. | OnKure raises $150M to advance breast cancer programs | 1 | Investing.com | ||
| 06.11.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 325 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,840 | -0,27 % | Gewinner der Börsengeschichte: +3.923.693 % Rendite und ein Top ESG-Score? Ja, das geht! | © Foto: Frank Rumpenhorst - dpaNachhaltigkeit und eine hohe Rendite schließen sich nicht aus. Im Gegenteil: Diese ESG-Aktie schaffte es unter die Top 30 der US-Aktien mit der höchsten Buy-and-Hold-Rendite... ► Artikel lesen | |
| INNOCAN PHARMA | 1,390 | -1,42 % | Nach Umsatzrückgang: InnoCan Pharma löst sich von Amazon-Fessel | ||
| ASSEMBLY BIOSCIENCES | 30,550 | 0,00 % | Assembly Biosciences-Aktie: UBS startet Coverage mit Ziel 52 US$ - Mizuho erhöht Rating | Die Neubewertung von Assembly Biosciences gewinnt weiter an Dynamik. Nachdem Partner Gilead Sciences mit der Auswahl von GS-1179 für die Phase 2 und der möglichen Ausweitung des Programms auf Präventionsanwendungen... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 65,60 | +1,11 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,215 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| OPKO HEALTH | 1,350 | +3,05 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| JAGUAR HEALTH | 0,418 | +0,82 % | Jaguar Health, Inc.: Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs | Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI... ► Artikel lesen | |
| OPUS GENETICS | 4,100 | +9,63 % | Opus Genetics stock rating reaffirmed at Buy by H.C. Wainwright | ||
| SOLIGENIX | 0,375 | -0,77 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| KALA BIO | 0,545 | +1,32 % | KALA BIO, Inc.: Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program | ARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have finalized a definitive exclusive distribution... ► Artikel lesen | |
| PROTHENA | 8,212 | -0,05 % | Prothena Corporation plc: Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,995 | +0,67 % | NRx Pharmaceuticals, Inc.: FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval | FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.Remaining item relates to manufacturer certification... ► Artikel lesen | |
| EVOLUS | 7,930 | +3,74 % | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| NEUROGENE | 32,400 | 0,00 % | Neurogene stock price target lowered to $65 by H.C. Wainwright | ||
| ACLARIS THERAPEUTICS | 5,215 | +0,10 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory... ► Artikel lesen |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.